Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort
NCT ID: NCT07163637
Last Updated: 2025-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
324 participants
INTERVENTIONAL
2025-09-08
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Does L. reuteri DSM 17648 reduce the frequency of the symptoms of upper gastrointestinal discomfort, including acid reflux-related and dyspeptic symptoms, and its relief rate, over 8 weeks of intake?
2. Does L. reuteri DSM 17648 improve gastrointestinal-related quality of life, and perceived stress?
3. How well do participants tolerate the L. reuteri DSM 17648 supplement?
4. Does L. reuteri DSM 17648 have an effect on the gut microbiota? (Exploratory aim)
Researchers will compare supplement containing L. reuteri DSM 17648 to a placebo (a look-alike supplement capsule that contains no L. reuteri DSM 17648).
Participants will:
* Take L. reuteri DSM 17648 supplement or a placebo every day for 8 weeks
* Answer questionnaires once every 2 weeks
* Provide stool samples for microbiome assessment at 2 timepoints (baseline and end of study (8 weeks))
* provide weekly information on investigational product intake and any adverse event records
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile
NCT02216825
Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population
NCT01837940
Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults
NCT01568567
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals
NCT07336615
The Effect of Lactobacillus Reuteri Probiotic as an Adjunct Treatment for Helicobacter Pylori Infection in Adults
NCT05399862
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Limosilactobacillus reuteri DSM 17648
Participant will take one capsule of L. reuteri DSM 17648 once per day with liquid during or immediately after the main meal, for 8 weeks.
Limosilactobacillus reuteri DSM 17648
One capsule containing L. reuteri DSM 17648 should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
Placebo
Participant will take one capsule of placebo once per day with liquid during or immediately after the main meal, for 8 weeks.
Placebo
One capsule of placebo should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Limosilactobacillus reuteri DSM 17648
One capsule containing L. reuteri DSM 17648 should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
Placebo
One capsule of placebo should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Anyone with a BMI less than or equal to 32 kg/m².
3. Be aged 30-70.
4. Anyone currently experiencing occasional upper gastrointestinal discomfort (approximately 2 times/week over the past month), including the following:
1. Heartburn
2. Upper abdominal pain
3. Reflux
4. Pain or burning in the stomach
5. Anyone with an FSSG (Frequency Scale for the Symptoms of GERD) total score of 8 or above.
6. Anyone who is generally healthy - does not live with any uncontrolled chronic health conditions, such as cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.
7. Willing to avoid introducing any new supplements, over-the-counter medications, or herbal remedies for the duration of this trial
8. If taking other supplements, over-the-counter medications, or herbal remedies unrelated to gut health, has been doing so consistently for a minimum of three months.
9. Willing to maintain current diet, sleep pattern, and activity levels for the duration of the trial.
10. Resides in the United States.
Exclusion Criteria
2\. Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
3\. Anyone unwilling to follow the study protocol. 4. Anyone taking any supplement, over-the-counter medication, or herbal remedy targeting gut health.
5\. Anyone with a known history of severe digestive disorders like GERD (Gastroesophageal Reflux Disease) and FD (Functional Dyspepsia), Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, celiac disease, chronic constipation, chronic diarrhea, or gastrointestinal tract disorders or surgeries.
6\. Anyone currently or recently (within the past 2 weeks) taking probiotic foods, including yoghurts.
7\. Anyone currently or recently (within the last 12 weeks) taking medication, including proton pump inhibitors, anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, monoamine oxidase inhibitors (MAOIs), or thyroid products.
8\. Currently partaking in another research study or will partake in any other research study for the next eight weeks or at any point during this study's duration.
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Citruslabs
INDUSTRY
Novozymes A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Swathi Varanasi
Role: PRINCIPAL_INVESTIGATOR
Citruslabs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citruslabs
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HHB-IM-24-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.